Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:11:05.507Z.
Calculation as of: 2026-10-06T14:11:05.507Z.
Quote observation: 2026-10-06T14:10:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dd458a7b7530169a13c79e175a6610edc18df904cb2af71895118b3708428af2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$58.97M
PS Ratio
N/A
TTM Avg
11308.43
3Y Avg
6194.66
5Y Avg
6194.66
Market Cap
$55.94M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | $58.66M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $58.83M | N/A | 4.74 | 4.40 | 4.40 |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.91M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.97M | N/A | 11308.43 | 6194.66 | 6194.66 |
| Adicet Bio, Inc. (ACET)vs › | $59.97M | N/A | 16.03 | 122.62 | 125.37 |
| Spectral AI, Inc. (MDAI)vs › | $56.65M | 3.74 | 2.63 | 1.90 | 4.28 |
| eXoZymes, Inc. (EXOZ)vs › | $55.97M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $55.94M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $54.90M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $62.78M | 0.79 | 0.69 | 0.95 | 1.63 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
